NSC 693868GSK-3 inhibitor. Also inhibits cdks CAS# 40254-90-8 |
2D Structure
- 3,3'-Diindolylmethane
Catalog No.:BCC1306
CAS No.:1968-05-4
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- Betulinic acid
Catalog No.:BCN5524
CAS No.:472-15-1
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 40254-90-8 | SDF | Download SDF |
PubChem ID | 438981 | Appearance | Powder |
Formula | C9H7N5 | M.Wt | 185.19 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | 2H-pyrazolo[4,3-b]quinoxalin-3-amine | ||
SMILES | C1=CC2=NC3=C(NN=C3N=C2C=C1)N | ||
Standard InChIKey | DWHVZCLBMTZRQM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C9H7N5/c10-8-7-9(14-13-8)12-6-4-2-1-3-5(6)11-7/h1-4H,(H3,10,12,13,14) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inhibitor of cyclin-dependent kinases (cdks) and glycogen synthase kinase-3 (GSK-3). IC50 values are 0.6, 0.4 and 1 μM for cdk1/cyclin B, cdk5/p25 and GSK-3 respectively. |
NSC 693868 Dilution Calculator
NSC 693868 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.3999 mL | 26.9993 mL | 53.9986 mL | 107.9972 mL | 134.9965 mL |
5 mM | 1.08 mL | 5.3999 mL | 10.7997 mL | 21.5994 mL | 26.9993 mL |
10 mM | 0.54 mL | 2.6999 mL | 5.3999 mL | 10.7997 mL | 13.4996 mL |
50 mM | 0.108 mL | 0.54 mL | 1.08 mL | 2.1599 mL | 2.6999 mL |
100 mM | 0.054 mL | 0.27 mL | 0.54 mL | 1.08 mL | 1.35 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- DMeOB
Catalog No.:BCC7213
CAS No.:40252-74-2
- Acetylcimigenol 3-O-alpha-L-arabinopyranside
Catalog No.:BCN1447
CAS No.:402513-88-6
- ONO-AE3-208
Catalog No.:BCC1822
CAS No.:402473-54-5
- Glycitin
Catalog No.:BCN5895
CAS No.:40246-10-4
- 5-O-Feruloylquinic acid
Catalog No.:BCN3788
CAS No.:40242-06-6
- H-Hyp-OMe.HCl
Catalog No.:BCC3248
CAS No.:40216-83-9
- H-Orn-OMe.2HCl
Catalog No.:BCC3001
CAS No.:40216-82-8
- Fmoc-β-Homo-Gln(Trt)-OH
Catalog No.:BCC2647
CAS No.:401915-55-7
- Fmoc-β-homo-Arg(Pbf)-OH
Catalog No.:BCC2649
CAS No.:401915-53-5
- Andarine
Catalog No.:BCC1168
CAS No.:401900-40-1
- SKA 31
Catalog No.:BCC7743
CAS No.:40172-65-4
- Boc-N-Me-Phe.DCHA
Catalog No.:BCC3348
CAS No.:40163-88-0
- Firategrast
Catalog No.:BCC1575
CAS No.:402567-16-2
- Deacetylcinobufagin
Catalog No.:BCN2720
CAS No.:4026-95-3
- SB 399885 hydrochloride
Catalog No.:BCC7595
CAS No.:402713-81-9
- 7-Methoxyneochamaejasmine A
Catalog No.:BCN3134
CAS No.:402828-38-0
- DR 4485 hydrochloride
Catalog No.:BCC7990
CAS No.:402942-53-4
- Telaprevir (VX-950)
Catalog No.:BCC2107
CAS No.:402957-28-2
- MDL 12330A hydrochloride
Catalog No.:BCC7066
CAS No.:40297-09-4
- Cassyfiline
Catalog No.:BCN4763
CAS No.:4030-51-7
- p-Menth-1-ene-3,6-diol
Catalog No.:BCN5454
CAS No.:4031-55-4
- Isoneobavaisoflavone
Catalog No.:BCN3195
CAS No.:40357-43-5
- Obtusafuran methyl ether
Catalog No.:BCN8103
CAS No.:40357-59-3
- Cannabisin H
Catalog No.:BCN3896
CAS No.:403647-08-5
VEGF alleviates ALS-CSF induced cytoplasmic accumulations of TDP-43 and FUS/TLS in NSC-34 cells.[Pubmed:28163215]
J Chem Neuroanat. 2017 Apr;81:48-52.
Cytoplasmic mislocalisation and aggregation of TDP-43 and FUS/TLS proteins in spinal motor neurons contribute to the pathogenesis of the highly fatal disorder amyotrophic lateral sclerosis (ALS). We investigated the neuroprotective effect of VEGF on expression of these proteins in the motor neuronal cell line NSC-34 modelled to reminisce sporadic form of ALS. We studied the expression of TDP-43 and FUS/TLS proteins after exposure to ALS-CSF and following VEGF supplementation by quantitative confocal microscopy and electron microscopy. ALS-CSF caused cytoplasmic overexpression of both the proteins and stress-granule formation in the cells. These alterations were alleviated by VEGF supplementation. The related ultrastructural changes like nuclear membrane dysmorphism and p-bodies associated changes were also reversed. However the protein expression did not completely translocate to the nucleus, as some cells continued to show to cytoplasmic mislocalisation. Thus, the present findings indicate that VEGF alleviates TDP43 and FUS pathology by complimenting its role in controlling apoptosis and reversing choline acetyl transferase expression. Hence, VEGF appears to target multiple pathogenic processes in the neurodegenerative cascade of ALS.
Important modifications by sugammadex, a modified gamma-cyclodextrin, of ion currents in differentiated NSC-34 neuronal cells.[Pubmed:28049438]
BMC Neurosci. 2017 Jan 3;18(1):6.
BACKGROUND: Sugammadex (SGX) is a modified gamma-cyclodextrin used for reversal of steroidal neuromuscular blocking agents during general anesthesia. Despite its application in clinical use, whether SGX treatment exerts any effects on membrane ion currents in neurons remains largely unclear. In this study, effects of SGX treatment on ion currents, particularly on delayed-rectifier K(+) current [I K(DR)], were extensively investigated in differentiated NSC-34 neuronal cells. RESULTS: After cells were exposed to SGX (30 muM), there was a reduction in the amplitude of I K(DR) followed by an apparent slowing in current activation in response to membrane depolarization. The challenge of cells with SGX produced a depolarized shift by 15 mV in the activation curve of I K(DR) accompanied by increased gating charge of this current. However, the inactivation curve of I K(DR) remained unchanged following SGX treatment, as compared with that in untreated cells. According to a minimal reaction scheme, the lengthening of activation time constant of I K(DR) caused by cell treatment with different SGX concentrations was quantitatively estimated with a dissociation constant of 17.5 muM, a value that is clinically achievable. Accumulative slowing in I K(DR) activation elicited by repetitive stimuli was enhanced in SGX-treated cells. SGX treatment did not alter the amplitude of voltage-gated Na(+) currents. In SGX-treated cells, dexamethasone (30 muM), a synthetic glucocorticoid, produced little or no effect on L-type Ca(2+) currents, although it effectively suppressed the amplitude of this current in untreated cells. CONCLUSIONS: The treatment of SGX may influence the amplitude and gating of I K(DR) and its actions could potentially contribute to functional activities of motor neurons if similar results were found in vivo.
Adult NSC diversity and plasticity: the role of the niche.[Pubmed:27978480]
Curr Opin Neurobiol. 2017 Feb;42:68-74.
Adult somatic stem cells are generally defined as cells with the ability to differentiate into multiple different lineages and to self-renew during long periods of time. These features were long presumed to be represented in one single tissue-specific stem cell. Recent development of single-cell technologies reveals the existence of diversity in fate and activation state of somatic stem cells within the blood, skin and intestinal compartments [1] but also in the adult brain. Here we review how recent advances have expanded our view of neural stem cells (NSCs) as a diverse pool of cells and how the specialized microenvironment in which they reside acts to maintain this diversity. In addition, we discuss the plasticity of the system in the injured brain.
c-Jun Amino-Terminal Kinase is Involved in Valproic Acid-Mediated Neuronal Differentiation of Mouse Embryonic NSCs and Neurite Outgrowth of NSC-Derived Neurons.[Pubmed:28321599]
Neurochem Res. 2017 Apr;42(4):1254-1266.
Valproic acid (VPA), an anticonvulsant and mood-stabilizing drug, can induce neuronal differentiation, promote neurite extension and exert a neuroprotective effect in central nervous system (CNS) injuries; however, comparatively little is known regarding its action on mouse embryonic neural stem cells (NSCs) and the underlying molecular mechanism. Recent studies suggested that c-Jun N-terminal kinase (JNK) is required for neurite outgrowth and neuronal differentiation during neuronal development. In the present study, we cultured mouse embryonic NSCs and treated the cells with 1 mM VPA for up to 7 days. The results indicate that VPA promotes the neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons; moreover, VPA induces the phosphorylation of c-Jun by JNK. In contrast, the specific JNK inhibitor SP600125 decreased the VPA-stimulated increase in neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons. Taken together, these results suggest that VPA promotes neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons. Moreover, JNK activation is involved in the effects of VPA stimulation.
Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors.[Pubmed:11983514]
Bioorg Med Chem. 2002 Jul;10(7):2177-84.
Protein kinases are involved in most physiological processes and in numerous diseases. Therefore, inhibitors of protein kinases have therefore a wide therapeutic potential. While screening for inhibitors of cyclin-dependent kinases (CDK's) and glycogen synthase kinase-3 (GSK-3), we identified pyrazolo[3,4-b]quinoxalines as sub-micromolar inhibitors of CDK1/cyclin B. A preliminary structure-activity relationship study suggests that this family of compounds can be optimized to inhibit CDK's and GSK-3. Compounds were tested for their anti-proliferative activity and the results show that several of them displayed a significant inhibitory effect on CDK1/cyclin B. The most active compound (1) was also tested against the brain kinases CDK5/p25 and GSK-3, and proved to be a good inhibitor of both of them. On the contrary, none of the compounds showed any activity in the CDC25 phosphatase assay. As an additional approach, affinity chromatography on immobilized pyrazolo[3,4-b]quinoxalines will be used to identify the intracellular targets of this family of compounds.